A randomised placebo controlled trial of itraconazole in the treatment of fungal-sensitised patients with severe asthma and without ABPA. - FAST

South Manchester University Hospitals NHS Trust0 个研究点目标入组 104 人开始时间: 2005年6月29日最近更新: 2013年7月15日

试验速览

暂无简介。

•Asthma requiring
•high dose inhaled steroids of >1000ug of beclomethasone or >500ug fluticasone or equivalent or continous steroids (>5mg prednisolone or equivalent for > 6 months or at least 4 courses over previous 12 months or 6 courses over previous 24 months and
•Skin test reactivity to at least one fungal preparation significantly greater than control or a positive RAST test to at least 1 fungal antigen
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•ABPA (any of the following exclude the patient:IgE > 1000, Aspergillus precipitins positive, Aspergillus specific IgG positive, fleeting pulmonary shadows.
•Recurrent bacterial chest infecitons
•Allergy to azoles
•Pregnancy ( all potentially fertile women to use contraception)
•Current treamtent with drugs that potentially interact with itraconazole and which cannot be stopped.
•Significant cardiac disease
•Significant immunosuppression
•Abnormal liver function
•Prior treatment with itraconazole in previous 8 months for > 2 days.
•Current URTI in last 4 weeks.

发起方

South Manchester University Hospitals NHS Trust